BRAF inhibitors are primarily used in the treatment of cancers that are driven by mutations in the BRAF gene, particularly melanoma. These inhibitors work by blocking the activity of the mutated BRAF protein, which is involved in promoting the growth and survival of cancer cells. By inhibiting this protein, BRAF inhibitors can slow down or stop the progression of the cancer. They are often used in combination with other therapies, such as MEK inhibitors, to enhance their effectiveness and reduce the likelihood of resistance. In addition to melanoma, BRAF inhibitors are also being investigated for their potential use in treating other types of cancers, such as colorectal cancer and thyroid cancer, where BRAF mutations are present. The use of these inhibitors has significantly improved outcomes for patients with BRAF-mutated cancers, offering a targeted approach to treatment that can be more effective and less toxic than traditional chemotherapy.